Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to cut blood transfusions for MDS patients

NCT ID NCT07422480

Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 18, 2026 · Updated 4 times

Summary

This Phase 3 trial compares elritercept to epoetin alfa in 300 adults with low- to intermediate-risk myelodysplastic syndromes (MDS) who need red blood cell transfusions. The main goal is to see if elritercept can help patients go without transfusions for at least 12 weeks while raising hemoglobin levels. The study also looks at quality of life and safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
elritercept (also called TAK-226) and epoetin alfa
What this could lead to
If elritercept works better than epoetin alfa, it could offer a new option to reduce or avoid blood transfusions for people with MDS-related anemia.
What could go wrong
This is an early-stage Phase 3 trial with 300 participants, so results may not apply to everyone. Elritercept may not prove more effective or could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Oct 2033

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria 1. Male or female participants aged ≥ 18 years or older at time of signing the informed consent form (ICF). 2. Able to understand the purpose and risks of the trial and voluntarily sign an ICF prior to any trial-related procedures being conducted and authorization to use protected health information and personal data in accordance to national and local privacy regulations. 3. Documented diagnosis of myelodysplastic syndrome(s) (MDS) according to WHO 2016 classification that meets International Prognostic Scoring System - Revised (IPSS-R) classification of very low-, low-, or intermediate-risk disease, confirmed by central laboratory independent reviewer prior to randomization. Hemoglobin (Hgb), platelet, and absolute neutrophil count (ANC) values should be collected greater than (\>) 14 days after red blood cell (RBC) transfusion or greater than (\>) 7 days after platelet transfusion, unless otherwise considered to be pretransfusion values. 4. Bone marrow less than (\<) 5% blasts in an evaluable bone marrow collected at screening and confirmed by central pathology independent reviewer. 5. Endogenous serum erythropoietin s (EPO) level of \<500 U/L. Should be results from blood samples collected \>14 days following an RBC transfusion to evaluate for eligibility unless considered pretransfusion values. 6. Participant requires RBC transfusion, as documented by the following criteria. A transfusion requirement of 2 to 6 pRBCs units/8 weeks confirmed for a minimum of 8 weeks immediately preceding randomization. • Hgb levels at the time of or within 3 days prior to administration of a RBC transfusion must have been less than or equal to (≤) 9.0 grams per deciliter (g/dL) (5.6 millimoles per liter (mmol/L)) with symptoms of anemia (or ≤7 g/dL \[4.3 mmol/L\] in the absence of symptoms) in order for the transfusion to be counted towards meeting eligibility criteria. • RBC transfusions administered when hemoglobin (Hgb) levels were \>9.0 g/dL (or \>7 g/dL in the absence of symptoms) and/or RBC transfusions administered for elective surgery, infections or bleeding events will not qualify as a required transfusion for the purpose of meeting eligibility criteria or stratification. 7. Hgb \<11.0 g/dL (6.8 mmol/L) after last RBC transfusion preceding randomization. Local laboratory is acceptable to facilitate randomization. 8. Eastern Cooperative Oncology Group score of 0, 1, or 2. Exclusion Criteria <!-- --> 1. Prior therapy with any of the following: 1. Epoetin alfa • At the investigator's discretion in consultation with the medical monitor, may be allowed if received no more than 2 doses of only epoetin alfa ≥8 weeks prior to randomization. No other erythropoiesis-stimulating agent (ESA) agent is allowed. 2. Darbepoetin 3. Granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor administered ≤8 weeks (56 days) prior to randomization unless given for treatment of febrile neutropenia. 4. Immunomodulatory drug (IMiDs) including lenalidomide • At the investigator's discretion in consultation with the medical monitor may be allowed if received ≤1 week of an IMiD ≥8 weeks prior to randomization. 5. Hypomethylating agent • At the investigator's discretion, in consultation with the medical monitor may be allowed if received no more than 2 doses ≥8 weeks prior to randomization. 6. Luspatercept, sotatercept, imetelstat, or elritercept 7. Immunosuppressive therapy 8. Hematopoeitic cell transplant 9. Iron chelation if administered ≤8 weeks prior to randomization. Participants on stable doses of iron chelation therapy for ≥8 weeks are allowed Vitamin B12 or folate therapy initiated within 4 weeks prior to randomization. Participants on stable replacement doses for ≥4 weeks and without ongoing concurrent vitamin B12 or folate deficiency are allowed. 10. Androgen use within 8 weeks before randomization. Participants on stable androgen dosing for hypogonadism for ≥8 weeks are allowed 11. High-dose corticosteroid use within 4 weeks before randomization. Participants on stable chronic steroid doses of prednisone ≤10 mg/day or corticosteroid equivalent for ≥ 4 weeks are allowed. Other disease modifying treatments for autoimmune diseases may be allowed upon medical monitor review. 12. Investigational agent or any other agent intended for treatment MDS treatment 2. Diagnosed to have MDS associated with del(5q) cytogenetic abnormality or MDS unclassifiable according to WHO 2016 classification or secondary MDS. 3. Known history of diagnosis of acute myeloid leukemia (AML). 4. Anemia due to any other known cause including but not limited to thalassemia; hypothyroidism; due to iron, vitamin B12, vitamin B6, zinc, or folate deficiencies; autoimmune or hereditary hemolytic anemia; any type of known clinically significant bleeding or sequestration or drug induced anemia, hemolytic anemia, or bleeding events. 5. Clinically significant cardiovascular disease defined as: 1. New York Heart Association heart disease class III or IV 2. Fridericia corrected QT (QTcF) interval \>500 milliseconds during screening 3. Uncontrolled arrhythmia, myocardial infarction, or unstable angina within 6 months before screening 6. Known ejection fraction \<35%, confirmed by a local echocardiogram performed during screening, or a previously performed echocardiogram if collected within 6 months before screening. 7. Medical history of thromboembolic events within 6 months before screening, including history of cerebrovascular accident (including ischemic, embolic, and hemorrhagic cerebrovascular accident), transient ischemic attack, deep venous thrombosis (DVT; including proximal and distal), pulmonary or arterial embolism, arterial thrombosis or other venous thrombosis. Participants with prior superficial thrombophlebitis are allowed. 8. Uncontrolled hypertension, defined as repeated elevations of systolic blood pressure of ≥160 millimeters of mercury (mmHg) and/or diastolic blood pressure ≥100 mmHg despite adequate treatment. 9. Prior history of malignancies, other than MDS. Participants who are free of other malignant disease for ≥3 years and have completed treatment, including maintenance are allowed. Participants with a history or concurrent diagnosis of the following conditions are allowed if not requiring systemic therapy: 1. Basal or squamous cell carcinoma of the skin; 2. Carcinoma in situ of the cervix; 3. Carcinoma in situ of the breast; 4. Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, node, metastasis \[TNM\] clinical staging system). 10. History of solid organ or bone marrow transplantation. 11. Active infection requiring intravenous antibiotics within 28 days or oral antibiotics within 14 days before randomization. 12. Known positive for human immunodeficiency virus (HIV), active infectious hepatitis B virus (HBV), or active infectious hepatitis C virus (HCV). Participants without known positive history of HIV, HBV, and/or HCV do not require further testing, unless testing is mandated per local guidelines. 13. Body mass index ≥ 40 kilograms per square meter (kg/m\^2). 14. Major surgery within 28 days before randomization. 15. New-onset seizures or poorly controlled seizures within 12 weeks prior to randomization are excluded from trial participation. 16. History of allergy/anaphylaxis to investigational product (including epoetin alfa) excipients (refer to the current elritercept investigator's brochure for a list of excipients) or recombination proteins. 17. History of pure red cell aplasia and/or antibody against erythropoietin (EPO). 18. Any of the following laboratory abnormalities: 1. ANC \<500/microliter (μL) (0.5×109/L). 2. Platelet count \<50,000/μL (50×109/L) or ≥450,000/μL (450×109/L). 3. Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥3× upper limit of the normal (ULN). 4. Total bilirubin ≥2×ULN. Participants with known history of Gilbert syndrome with unconjugated bilirubin \<3×ULN are allowed. Higher levels if attributed to active RBC precursor destruction within the bone marrow (ineffective erythropoiesis) may be allowed upon medical monitor review. 5. Estimated glomerular filtration rate \<30 mL/min/1.73 m\^2 as determined by the Chronic Kidney Disease Epidemiology (CKD-EPI) collaboration equation. 6. Ferritin ≤50 micrograms per liter (μg/L). 7. Folate ≤2.0 nanograms per milliliter (ng/mL). 8. Vitamin B12 ≤200 picograms per milliliter (pg/mL). 19. Ongoing participation in another interventional clinical trial. 20. Participant is unwilling or in the opinion of the investigator the participant is unable to comply with the requirements of the protocol. 21. Is a participant of childbearing potential (POCBP) but does not agree to use at least 1 form of highly effective contraception from the time of signing the ICF until at least 60 days after the last dose of trial intervention. 22. Participants of male birth who are fertile and who have partners of childbearing potential, who do not agree to use acceptable barrier contraception, that is, a male condom during the entire trial intervention period until at least 60 days after the last dose of trial intervention. 23. If applicable, participant with a positive serum pregnancy test during the screening period or known to be pregnant or a lactating participant who does not agree to forego breastfeeding during the entire trial intervention period until at least 60 days after the last dose of trial intervention. 24. For Participants in France: Persons under court protection, persons not affiliated with a social security system, and protected adults.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anemia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anemia myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anemia Myelodysplastic syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    162 sites in 28 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • AIMS, Kochi

    NOT_YET_RECRUITING

    Kochi, Kerala, 682041, India

  • AZ Delta (H.-Hartziekenhuis Roeselare-Menen vzw (HHRM)) - Campus Rumbeke

    NOT_YET_RECRUITING

    Roeselare, West Flanders, 8800, Belgium

  • AidPort

    RECRUITING

    Skorzewo, Wielkopolska, 60185, Poland

  • Albert Einstein College - Montefiore

    RECRUITING

    The Bronx, New York, 10467, United States

  • Alfred Hospital

    NOT_YET_RECRUITING

    Richmond, Victoria, 3004, Australia

  • American Oncology Partners P.A. MidAmerica Cancer Care

    RECRUITING

    Kansas City, Missouri, 64132, United States

  • Amsterdam UMC-Locatie VUMC (Vrije Universiteit Medisch Centrum)

    RECRUITING

    Amsterdam, North Holland, 1081HV, Netherlands

  • Ankara Universitesi, TAp FakAltesi, Hematoloji BD

    NOT_YET_RECRUITING

    Ankara, Ankara, Turkey, 06520, Turkey (Türkiye)

  • Apollo Hospital Hyderabad

    NOT_YET_RECRUITING

    Hyderabad, Telangana, 500096, India

  • Azienda Ospedaliero Universitaria di Bologna - Policlinico S. Orsola-Malpighi - Istituto di Ematologia "Lorenzo e Ariosto Seragnoli"

    NOT_YET_RECRUITING

    Bologna, 40138, Italy

  • BRCR Medical Center Inc

    RECRUITING

    Tamarac, Florida, 33321, United States

  • Banner MD Anderson Cancer Center

    NOT_YET_RECRUITING

    Gilbert, Arizona, 85234, United States

  • Banphaeo General Hospital

    NOT_YET_RECRUITING

    Ban Phaeo, Samutsakorn, 74120, Thailand

  • Calvary Mater Newcastle

    NOT_YET_RECRUITING

    Waratah, New South Wales, 2282, Australia

  • Cancer & Blood Research Center

    NOT_YET_RECRUITING

    Whittier, California, 90270, United States

  • Centre Hospitalier Universitaire (CHU) de Nice - Hopital L'Archet I - Hematologie Clinique

    RECRUITING

    Nice, 06200, France

  • Centre Hospitalier Universitaire Grenoble Alpes

    NOT_YET_RECRUITING

    La Tronche, Isere, 38700, France

  • Centro de Hematologia e Oncologia (CHO)

    NOT_YET_RECRUITING

    Joinville, Santa Catarina, 89201-260, Brazil

  • Centro de Investigacion Clinica Chapultepec (CICC), S.A. de C.V

    NOT_YET_RECRUITING

    Morelia, Michoacán, 58260, Mexico

  • Chang Bing Show Chwan Memorial Hospital

    RECRUITING

    Changhua, 505029, Taiwan

  • Charite Campus Benjamin Franklin

    RECRUITING

    Berlin, 12200, Germany

  • China Medical University Hospital

    RECRUITING

    Taichung, TW, 404, Taiwan

  • Christian Medical College

    NOT_YET_RECRUITING

    Vellore, Tamil Nadu, 632517, India

  • Chu-Ucl Namur Site Godinne

    RECRUITING

    Yvoir, Namur, 5530, Belgium

  • Chugoku Central Hospital

    RECRUITING

    Fukuyama-shi, Hiroshima, 720-0001, Japan

  • Churchill Hospital

    NOT_YET_RECRUITING

    Oxford, OXON, OX3 7LE, United Kingdom

  • City of Hope - Comprehensive Cancer Center (CCC)

    NOT_YET_RECRUITING

    Duarte, California, 91010, United States

  • Cleveland clinic OH

    NOT_YET_RECRUITING

    Cleveland, Ohio, 44195, United States

  • Cork University Hospital

    RECRUITING

    Cork, T12 DC4A, Ireland

  • D'OR Institute for Research and Education

    NOT_YET_RECRUITING

    Salvador, Estado de Bahia, 41253-190, Brazil

  • Democritus University of Thrace (DUTH) - University General Hospital of Alexandroupolis

    NOT_YET_RECRUITING

    Alexandroupoli, Evros, 68100, Greece

  • Dokkyo Medical University Hospital

    RECRUITING

    Mibu, Tochigi, 321-0293, Japan

  • Dr. Pencho Georgiev - Outpatient Center for Individual Practice for Specialized Medical Care in Internal Medicine and Clinical Hematology (EOOD)

    RECRUITING

    Plovdiv, 4000, Bulgaria

  • Eastern Haematology & Oncology Group or Austin Hospital

    NOT_YET_RECRUITING

    Heidelberg, Victoria, 3084, Australia

  • Ege University Medical Faculty

    NOT_YET_RECRUITING

    Izmir, 35100, Turkey (Türkiye)

  • Emory University

    RECRUITING

    Atlanta, Georgia, 30322, United States

  • Epic Medical Research

    NOT_YET_RECRUITING

    Monroe, Louisiana, 71201, United States

  • Epic Medical Research - Shreveport

    NOT_YET_RECRUITING

    Shreveport, Louisiana, 71106, United States

  • Faculty of Medicine, School of Health Sciences, University of Ioannina

    NOT_YET_RECRUITING

    Ioannina, 45500, Greece

  • Filantropia Municipal Clinical Hospital

    NOT_YET_RECRUITING

    Craiova, Dolj, 20014, Romania

  • Fiona Stanley Hospital

    NOT_YET_RECRUITING

    Perth, Western Australia, 6150, Australia

  • Flinders Medical Centre

    NOT_YET_RECRUITING

    Bedford Park, South Australia, 5042, Australia

  • Fox Chase Cancer Center

    RECRUITING

    Philadelphia, Pennsylvania, 19111, United States

  • Fukushima Medical University Hospital

    RECRUITING

    Fukushima, Fukushima, Japan, 960-1295, Japan

  • Gemeinschaftspraxis fuer Haematologie und Onkologie - Praxis Steinfurter Strasse

    RECRUITING

    Münster, North Rhine-Westphalia, 48153, Germany

  • General Hospital of Thessaloniki "Ippokratio"

    NOT_YET_RECRUITING

    Thessaloniki, Macedonia, 55133, Greece

  • Gifu Municipal Hospital

    RECRUITING

    Gifu, Gifu, 500-8323, Japan

  • Gruppo Humanitas-Humanitas Research Hospital (Istituto Clinico Humanitas)

    NOT_YET_RECRUITING

    Rozzano, Milan, 20089, Italy

  • Gustave Roussy

    NOT_YET_RECRUITING

    Villejuif, X, 94805, France

  • Helse Bergen HF

    RECRUITING

    Bergen, Vest, 5021, Norway

  • Hematology Oncology Associates of Rockland

    NOT_YET_RECRUITING

    Nyack, New York, 10960, United States

  • Hospital 9 de Julho (Rede Americas/DASA)

    NOT_YET_RECRUITING

    São Paulo, 01409-000, Brazil

  • Hospital Amaral Carvalho (HAC)

    NOT_YET_RECRUITING

    Jaú, São Paulo, 17210080, Brazil

  • Hospital Mae de Deus, Clinical Research Unit - Cancer Institute

    NOT_YET_RECRUITING

    Porto Alegre, Rio Grande do Sul, 90110-270, Brazil

  • Hospital Privado de Cordoba

    NOT_YET_RECRUITING

    Córdoba, X5000, Argentina

  • Hospital Sultanah Aminah Johor Bahru (HSAJB)

    RECRUITING

    Johor Bahru, Johor, 80100, Malaysia

  • Hospital Sultanah Bahiyah (HSB) (Klinik Kesihatan Bandar Alor Setar/Hospital Alor Setar)

    RECRUITING

    Alor Star, Kedah, 11450, Malaysia

  • Hospital Universitari Vall d'Hebron-Institut de Recerca (VHIR)

    NOT_YET_RECRUITING

    Barcelona, 8035, Spain

  • Hospital Universitario Virgen de la Victoria (HUVV)

    RECRUITING

    Málaga, 29010, Spain

  • Hospital Universitario Virgen del Rocio (HUVR) - Instituto de Biomedicina de Sevilla (IBIS)

    NOT_YET_RECRUITING

    Seville, Seville, 41013, Spain

  • Hospital of Lithuania University of Health Sciences Kaunas, Clinic of Oncology and Hematology

    RECRUITING

    Kaunas, LT, 50161, Lithuania

  • Huntsman Cancer Institute

    NOT_YET_RECRUITING

    Salt Lake City, Utah, 84124, United States

  • Hyogo Prefectural Amagasaki General Medical Center

    RECRUITING

    Amagasaki-shi, Hyōgo, 660-8550, Japan

  • IRCCS Ospedale San Raffaele

    NOT_YET_RECRUITING

    Milan, 20132, Italy

  • Insel Gruppe AG

    NOT_YET_RECRUITING

    Bern, 3010, Switzerland

  • Institut Catala d'Oncologia (ICO) - Hospital Duran i Reynals Location

    NOT_YET_RECRUITING

    L'Hospitalet de Llobregat, Barcelona, 08908, Spain

  • Institute of Cancer Research and Treatment of Candiolo

    RECRUITING

    Candiolo, Torino, 10060, Italy

  • Instituto Medico de la Fundacion Estudios Clinicos

    NOT_YET_RECRUITING

    Rosario, Santa Fe Province, 2000, Argentina

  • Institutul Oncologic Prof. Dr. I. Chiricu

    RECRUITING

    Cluj-Napoca, Cluj, 400124, Romania

  • Irmandade da Santa Casa da Misericordia de Santos (ISCMS)

    NOT_YET_RECRUITING

    Santos, São Paulo, 11075-101, Brazil

  • Istanbul Florence Nightingale Hospital

    NOT_YET_RECRUITING

    Istanbul, 34381, Turkey (Türkiye)

  • Kantonsspital Graubunden

    NOT_YET_RECRUITING

    Chur, Kanton Graubünden, 7000, Switzerland

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    RECRUITING

    Kaohsiung City, 807, Taiwan

  • King Chulalongkorn Memorial Hospital

    NOT_YET_RECRUITING

    Bangkok, 10330, Thailand

  • King's College Hospital

    RECRUITING

    London, SE5 9RS, United Kingdom

  • Korea University Anam Hospital

    NOT_YET_RECRUITING

    Seoul, 02841, South Korea

  • LUMI Research

    RECRUITING

    Houston, Texas, 77090, United States

  • Laiko General Hospital

    NOT_YET_RECRUITING

    Athens, Central Athens, 11526, Greece

  • Maharaj Nakorn Chiangmai Hospital

    NOT_YET_RECRUITING

    Chiang Mai, Chiang Mai, 50200, Thailand

  • Mater Misericordiae University Hospital

    NOT_YET_RECRUITING

    Dublin, Dublin 7, Ireland

  • Max SuperSpeciality Saket, Delhi

    NOT_YET_RECRUITING

    Delhi, 110017, India

  • Mersin Medicalpark Hospital

    NOT_YET_RECRUITING

    Mersin, Mezitli, 33000, Turkey (Türkiye)

  • Mid North Coast Local Health District - Mid North Coast Cancer Institute (MNCCI) - Coffs Harbour

    NOT_YET_RECRUITING

    Coffs Harbour, New South Wales, 2450, Australia

  • Moffitt Cancer Center

    NOT_YET_RECRUITING

    Tampa, Florida, 33612, United States

  • Monash University-Monash Medical Centre (MMC) - Clayton

    NOT_YET_RECRUITING

    Clayton, Victoria, 3168, Australia

  • NHO Nagoya Medical Center

    RECRUITING

    Nagoya, Aichi-ken, 460-0001, Japan

  • NTT Medical Center Tokyo

    RECRUITING

    Shinagawa-ku, Tokyo, 141-8625, Japan

  • National Cheng Kung University Hospital

    RECRUITING

    Tainan, 704, Taiwan

  • National Institute of Medical Sciences and Nutrition Salvado

    NOT_YET_RECRUITING

    Mexico City, 14080, Mexico

  • National Taiwan University Hospital - East Campus

    RECRUITING

    Taipei, 100225, Taiwan

  • National and Kapodistrian University of Athens (NKUA)-Laiko General Hospital

    NOT_YET_RECRUITING

    Athens, Central Athens, 11527, Greece

  • National and Kapodistrian University of Athens-University General Hospital Attikon

    NOT_YET_RECRUITING

    Athens, West Athens, 12462, Greece

  • Norton Cancer Institute

    RECRUITING

    Louisville, Kentucky, 40207, United States

  • Novant Health Care Institute

    NOT_YET_RECRUITING

    Winston-Salem, North Carolina, 27106, United States

  • Oaxaca Site Management Organization S.C. - Oaxaca

    NOT_YET_RECRUITING

    Oaxaca City, 68000, Mexico

  • Ondokuz Mayis University School of Medicine, Department of Hematology

    NOT_YET_RECRUITING

    Samsun, Atakum, 55139, Turkey (Türkiye)

  • Orchard Healthcare Research Inc. (OHR) - Skokie

    RECRUITING

    Skokie, Illinois, 60077, United States

  • Oslo Universitetssykehus HF

    NOT_YET_RECRUITING

    Oslo, 0372, Norway

  • Ospedale Cardarelli

    NOT_YET_RECRUITING

    Naples, 80131, Italy

  • Ospedale di Novara

    RECRUITING

    Novara, 28100, Italy

  • Pilgrim Hospital

    RECRUITING

    Boston, Lincolnshire, PE227BU, United Kingdom

  • Poitiers University Hospital Center - Miletrie Site

    RECRUITING

    Poitiers, Vienne, 86021, France

  • Policlinico Umberto I

    NOT_YET_RECRUITING

    Roma, Rome, 00161, Italy

  • Polyclinic San Matteo, IRCCS, Department of Oncohematology, Operative Unit of Hematology

    NOT_YET_RECRUITING

    Pavia, PV, 27100, Italy

  • Porto Alegre Clinical Hospital (HCPA)

    NOT_YET_RECRUITING

    Porto Alegre, Rio Grande do Sul, 90035903, Brazil

  • Portuguese Charity of Sao Paulo, Clinical Hematology / Oncology Center

    NOT_YET_RECRUITING

    São Paulo, 01321-001, Brazil

  • Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh

    NOT_YET_RECRUITING

    Chandigarh, 160012, India

  • Pratia MCM Krakow

    NOT_YET_RECRUITING

    Krakow, maAopolska, 50-727, Poland

  • Pratia Onkologia Katowice

    RECRUITING

    Katowice, Silesian Voivodeship, 40-519, Poland

  • Pratia Wroclaw

    RECRUITING

    Wroclaw, Lower Silesian Voivodeship, 50-019, Poland

  • Praxis am Volkspark

    RECRUITING

    Berlin, 10715, Germany

  • Providence Medical Group

    NOT_YET_RECRUITING

    Santa Rosa, California, 95403, United States

  • Queen Elizabeth Hospital Birmingham

    NOT_YET_RECRUITING

    Birmingham, West Midlands, B15 2TH, United Kingdom

  • Renovatio Clinical

    NOT_YET_RECRUITING

    The Woodlands, Texas, 77380, United States

  • Royal Adelaide Hospital

    NOT_YET_RECRUITING

    Adelaide, South Australia, 5000, Australia

  • Sahyadri Hospitals, Pune

    NOT_YET_RECRUITING

    Pune, Maharashtra, 411004, India

  • Saint-Louis Hospital

    NOT_YET_RECRUITING

    Paris, 75010, France

  • Samsung Medical Center

    RECRUITING

    Seoul, 06351, South Korea

  • Sanatorio Allende S.A. - Nueva Cordoba

    NOT_YET_RECRUITING

    Córdoba, 5000, Argentina

  • Seoul National University Bundang Hospital

    RECRUITING

    Seongnam-si, Gyeonggi-do, 13620, South Korea

  • Seoul National University Hospital

    RECRUITING

    Seoul, 03080, South Korea

  • Soon Chun Hyang University Hospital Seoul

    RECRUITING

    Seoul, Yongsan-gu, 04401, South Korea

  • South Eastern Sydney Local Health District

    NOT_YET_RECRUITING

    Sydney, New South Wales, 2217, Australia

  • Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Clinic of Hematology

    RECRUITING

    Sofia, 1756, Bulgaria

  • St. James's Hospital

    NOT_YET_RECRUITING

    Dublin, 091 524411, Ireland

  • St. Vincent's Hospital Melbourne

    NOT_YET_RECRUITING

    Fitzroy, Victoria, 3065, Australia

  • Swiss Medical Center - Barrio Parque

    NOT_YET_RECRUITING

    Buenos Aires, 1425, Argentina

  • Sykehuset Vestfold HF

    RECRUITING

    Tønsberg, Vestfold, 3116, Norway

  • Szent Borbala Korhaz, Department of Internal Medicine and Haematology, Division of Hematology

    RECRUITING

    Tatabánya, Komárom-Esztergom, 2800, Hungary

  • Taipei Veterans General Hospital

    NOT_YET_RECRUITING

    Taipei, 112201, Taiwan

  • Tata Medical Center, Kolkata

    NOT_YET_RECRUITING

    Kochi, Kerala, 682041, India

  • Tennessee Oncology, PLLC

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Texas Oncology - Denton

    NOT_YET_RECRUITING

    Denton, Texas, 76201, United States

  • The Cancer and Hematology Centers

    NOT_YET_RECRUITING

    Grand Rapids, Michigan, 49503, United States

  • The Catholic University of Korea, Seoul St. Mary's Hospital

    RECRUITING

    Seoul, 06591, South Korea

  • The Center for Cancer and Blood Disorders

    RECRUITING

    Fort Worth, Texas, 76104, United States

  • The Christie NHS Foundation Trust

    NOT_YET_RECRUITING

    Manchester, M20 4BX, United Kingdom

  • The University of Texas-MD Anderson Cancer Center - Leukemia Center

    RECRUITING

    Houston, Texas, 77030, United States

  • Thomas Jefferson University

    NOT_YET_RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

  • Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital

    RECRUITING

    Bunkyo-ku, Tokyo, 113-8677, Japan

  • UZ Leuven

    RECRUITING

    Leuven, Vlaams-Brabant, 3000, Belgium

  • Universidad Autonoma de Nuevo Leon-Hospital Universitario "Dr. Jose Eleuterio Gonzalez" - Servicio de Hematologia

    NOT_YET_RECRUITING

    Monterrey, Nuevo León, 64460, Mexico

  • Universidad de Salamanca - Hospital Universitario de Salamanca

    RECRUITING

    Salamanca, 37007, Spain

  • Universita Degli Studi di Roma "Tor Vergata"

    NOT_YET_RECRUITING

    Rome, 00133, Italy

  • Universita degli Studi di Firenze - Azienda Ospedaliero-Universitaria Careggi (AOUC)

    NOT_YET_RECRUITING

    Florence, Florence, 50141, Italy

  • Universita degli Studi di Padova-Azienda Ospedaliera di Padova

    NOT_YET_RECRUITING

    Padua, 35128, Italy

  • Universitatsklinikum Bayreuth, Med. Klinik IV

    RECRUITING

    Bayreuth, Bavaria, 95445, Germany

  • Universitatsspital Zurich

    NOT_YET_RECRUITING

    Zurich, Canton of Zurich, 8091, Switzerland

  • Universiti Malaya - Faculty of Medicine (FOM)

    RECRUITING

    Kuala Lumpur, Kuala Lumpur, 59200, Malaysia

  • University Hospital Galway

    NOT_YET_RECRUITING

    Galway, H91 YR71, Ireland

  • University Hospital Halle (Saale), Department of Internal Medicine IV - Hematology and Oncology

    NOT_YET_RECRUITING

    Halle, Saxony-Anhalt, 06120, Germany

  • University Hospital Ramon y Cajal

    NOT_YET_RECRUITING

    Madrid, 28034, Spain

  • University Hospitals of Leicester NHS Trust

    NOT_YET_RECRUITING

    Leicester, Leicestershire, LE1 5WW, United Kingdom

  • University and Polytechnic Hospital La Fe

    RECRUITING

    Valencia, 46026, Spain

  • University of Debrecen Clinical Center, Clinic of Internal Medicine, Department of Hematology

    RECRUITING

    Debrecen, H-B, 500096, Hungary

  • University of Miami

    NOT_YET_RECRUITING

    Miami, Florida, 33136, United States

  • Vilniaus Universiteto Ligonine Santaros Klinikos (VULSK) (Vilniaus Universiteto Ligonines Santariskiu Klinikos)

    NOT_YET_RECRUITING

    Vilnius, 08661, Lithuania

  • Virginia Commonwealth University (VCU)-Medical Center - North Hospital

    NOT_YET_RECRUITING

    Richmond, Virginia, 23298, United States

  • Warszawski Uniwersytet Medyczny (WUM) (Medical University of Warsaw)

    RECRUITING

    Warsaw, Masovian Voivodeship, 02-172, Poland

  • West Virginia University Cancer Institute

    NOT_YET_RECRUITING

    Wheeling, West Virginia, 26003, United States

  • World Research Link

    RECRUITING

    Baytown, Texas, 77521, United States

  • Yale

    NOT_YET_RECRUITING

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.